This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Unwinding Illumina’s Grail deal will be a lengthy, and messy, process

By Natalie McNelis and Nicholas Hirst ( September 7, 2022, 17:38 GMT | Comment) -- Illumina will likely eventually have to unwind its acquisition of Grail as a result of the EU merger regulator’s block on it yesterday, but a number of steps must come first, notwithstanding any challenge to the decision by the US biotech giant. Because the case is unprecedented in more ways than one, there’s no clear playbook for what will happen next, or when, but some past cases do help to shed a little light.Illumina will likely eventually have to unwind its acquisition of Grail as a result of the EU merger regulator’s block on it yesterday, but a number of steps must come first, notwithstanding any challenge to the decision by the US biotech giant....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login